Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

MK3 MK3 + RBV
MK3 MK3 + RBV
by min-jolicoeur
Randomisation. Open-label. W8. * Liver biopsy or ...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
How to optimize treatment of G1 patients?
How to optimize treatment of G1 patients?
by KissesForYou
Prof. G. K. K. Lau 2012. Standard of care (SOC) ...
Out With the Old and In With the New, Again?
Out With the Old and In With the New, Again?
by test
Out With the Old, In With the New. Current Standa...
TURQUOISE-I
TURQUOISE-I
by natalia-silvester
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
TURQUOISE-I
TURQUOISE-I
by marina-yarberry
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by lois-ondreau
Sameh W. Boktor, MD, MPH. Medical Epidemiologist....
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by cheryl-pisano
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by myesha-ticknor
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by webraph
Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...
SOF/VEL
SOF/VEL
by trish-goza
400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV...
Current strategies for the management of treatment naïve a
Current strategies for the management of treatment naïve a
by min-jolicoeur
Mark S. Sulkowski, MD. Medical Director, Viral He...
Edited by
Edited by
by celsa-spraggs
Morris Sherman MD . BCh. PhD FRCP(C) . Associate...
Future HCV Treatment Paradigms
Future HCV Treatment Paradigms
by kittie-lecroy
Mark Sulkowski, MD . Professor of Medicine. Medic...
Direct Acting Antivirals: What are they? What is their pl
Direct Acting Antivirals: What are they? What is their pl
by tawny-fly
Mark Sulkowski, MD. Associate Professor of Medici...
Forns
Forns
by ellena-manuel
X. J . Hepatology. 2015; 63: 564-72. C-SALVAGE ...
OBV/PTV/r DSV Open label
OBV/PTV/r DSV Open label
by kittie-lecroy
≥ 18 years. Chronic HCV infection. Genotype 1. ...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Hepatitis C Imtiaz Alam, M.D.
Hepatitis C Imtiaz Alam, M.D.
by olivia-moreira
Medical Director, Austin Hepatitis Center. 1. Hep...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
M.W. Fried , 1 M. Buti,
M.W. Fried , 1 M. Buti,
by iamamercy
2. G.J. Dore,. 3. P. Ferenci,. 4. . I. Jacobson...
Are (exogenous) interferons
Are (exogenous) interferons
by amey
really necessary?. Peter . Ferenci. Medical Univer...
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
by badra
Duke University School of Medicine. Durham, North ...
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
Chronic hepatitis C: guidelines for screening and
Chronic hepatitis C: guidelines for screening and
by aaron
treatment. Lisa M. Glass, MD. Clinical Lecturer. ...
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection:
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection:
by kittie-lecroy
Interim Analysis of a French Multicenter Compassi...
Treatment of Hepatitis C in patients with
Treatment of Hepatitis C in patients with
by tatyana-admore
thalassaemia. . Where . are we now?. Telaprevir ....
Management of HCV in Co-Infected Patients
Management of HCV in Co-Infected Patients
by danika-pritchard
Marie-Louise Vachon, MD, . MSc. Division of . Inf...
Advances in Hepatitis C Identification and Treatment
Advances in Hepatitis C Identification and Treatment
by giovanna-bartolotta
Developed by Camilla S. Graham, MD, BIDMC, 5/5/15...
Daclatasvir in Combination With Sofosbuvir
Daclatasvir in Combination With Sofosbuvir
by mitsue-stanley
With Or Without Ribavirin Is Safe and Efficacious...
Daclatasvir in Combination With Sofosbuvir
Daclatasvir in Combination With Sofosbuvir
by mitsue-stanley
With Or Without Ribavirin Is Safe and Efficacious...
Resistance to Direct Acting Antiviral Therapy
Resistance to Direct Acting Antiviral Therapy
by tawny-fly
Resistance to HCV DAAs: What is the threat level...
Hepatitis C in PWIDS London:
Hepatitis C in PWIDS London:
by obrien
PARTNERSHIP TOWARDS ELIMINATION OF A MAJOR PUBLIC ...
SOF/VEL 400/100 mg qd N = 75
SOF/VEL 400/100 mg qd N = 75
by danika-pritchard
W24. SOF/VEL. >. 18 years. Chronic HCV infect...
Practical management of PI therapy
Practical management of PI therapy
by TropicalParadise
in Hepatitis C . Paris . Februari. 2012. Ola . We...
Treatment of Chronic Hepatitis C Virus Infection in Adults
Treatment of Chronic Hepatitis C Virus Infection in Adults
by tracy
www.hivguidelines.org. APRIL 2023. NYSDOH AIDS Ins...
TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-I
TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-I
by eloise
20. th. International AIDS Conference. • . Melb...
EASL 2019 HCV Conference Update
EASL 2019 HCV Conference Update
by sophia
April 10. –14. , 2019. Vienna, Austria. Disclaim...
Safety and Efficacy of Daclatasvir
Safety and Efficacy of Daclatasvir
by tabitha
. Plus . Sofosbuvir. With or Without Ribavirin . ...
EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF
EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF
by hezekiah
FALDAPREVIR (BI 201335) + BI 207127 ± RIBAVIRIN. ...